Griseofulvin
Fulvicin P/g, Fulvicin-u/f, Grifulvin, Gris-peg, Grisactin, Griseofulvin, Microsize, Ultragris, Ultramicrosize (griseofulvin) is a small molecule pharmaceutical. Griseofulvin was first approved as Grifulvin v on 1982-01-01. It is used to treat tinea capitis and tinea pedis in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Fulvicin p/g, Fulvicin-u/f, Gris-peg, Griseofulvin, Griseofulvin, ultramicrosize, Griseofulvin,ultramicrosize (discontinued: Grifulvin, Grisactin, Grisactin ultra)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Griseofulvin
+
ultramicrosize
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| GRIS-PEG | Bausch Health Companies | N-050475 RX | 1982-01-01 | 2 products, RLD |
Griseofulvin
+
microcrystalline
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| GRIFULVIN V | Johnson & Johnson | N-050448 DISCN | 1982-01-01 | 1 products, RLD |
| GRISACTIN | Wyeth | N-050051 DISCN | 1982-01-01 | 2 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| gris-peg | New Drug Application | 2010-06-01 |
| griseofulviin (microsize) | ANDA | 2012-09-26 |
| griseofulvin | ANDA | 2024-10-28 |
| griseofulvin microsize | ANDA | 2024-10-28 |
| ultramicrosize griseofulvin | ANDA | 2023-10-05 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| tinea pedis | EFO_0007512 | D014008 | B35.3 |
| tinea capitis | — | D014006 | B35.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
7 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tinea | D014005 | EFO_0007510 | B35.9 | — | — | 2 | — | 1 | 3 |
| Tinea capitis | D014006 | — | B35.0 | — | — | 2 | — | 1 | 3 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 1 | — | — | — | — | 1 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Griseofulvin |
| INN | griseofulvin |
| Description | Griseofulvin is an oxaspiro compound produced by Penicillium griseofulvum. It is used by mouth as an antifungal drug for infections involving the scalp, hair, nails and skin that do not respond to topical treatment. It has a role as an antibacterial agent and a Penicillium metabolite. It is an organochlorine compound, a member of 1-benzofurans, an oxaspiro compound, an antibiotic antifungal drug and a benzofuran antifungal drug. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O |
Identifiers
| PDB | — |
| CAS-ID | 126-07-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL562 |
| ChEBI ID | 27779 |
| PubChem CID | 441140 |
| DrugBank | DB00400 |
| UNII ID | 32HRV3E3D5 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Griseofulvin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,508 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
240 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use